Myra Solano Garcia, who has Alzheimer's, says the drug Kisunla may be one reason she can still drive, cook, and sing.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

"I think it helped," says her husband, Ken Bell. "But I'm not sure." That sort of uncertainty is common when it comes to ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out ...

The Food and Drug Administration approved the drug, now marketed as Kisunla, in July of 2024. It's one of two drugs approved since 2023 that can clear the brain of sticky amyloid plaques ...